Who Pays My Doctor?

Healthcare provider profile · identity verified

Haley Hoy, APRN

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · NASHVILLE, TN · NPI 1265564561

Profile state: payments only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Haley Hoy, APRN received $179,740.14 in general payments during 2025 across 142 reported records.

Pulmonx Corporation accounted for 93.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 17 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$179,740.14

142 reported records · 14 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Pulmonx Corporation Unresolved — no canonical attribution shown $168,576.3293.8%1152025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $9,712.225.4%132025
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $250.000.1%12025
Mallinckrodt Hospital Products Inc. Unresolved — no canonical attribution shown $217.710.1%22025
Inspire Medical Systems, Inc. Unresolved — no canonical attribution shown $143.770.1%12025
Amgen Inc. Unresolved — no canonical attribution shown $139.480.1%12025
GENZYME CORPORATION Unresolved — no canonical attribution shown $132.200.1%22025
Actelion Pharmaceuticals US, Inc. Unresolved — no canonical attribution shown $121.370.1%12025
Alexion Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $117.720.1%12025
Ardelyx, Inc. Unresolved — no canonical attribution shown $117.720.1%12025
Insmed, Inc. Unresolved — no canonical attribution shown $87.660.1%12025
Genentech, Inc. Unresolved — no canonical attribution shown $83.550.1%12025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $21.500.0%12025
Novo Nordisk Inc Unresolved — no canonical attribution shown $18.920.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Consulting Fee$139,576.3627
Travel and Lodging$25,170.2040
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$8,060.005
Food and Beverage$6,833.5969
Education$99.991

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
ZEPHYR ENDOBRONCHIAL VALVE
Normalized: zephyr endobronchial valve		 Device Pulmonx Corporation $168,576.32 115 2025
Source payment records
CHARTIS CATHETER
Normalized: chartis catheter		 Device Pulmonx Corporation $117,215.68 100 2025
Source payment records
PULMONX CHARTIS TABLET CONSOLE
Normalized: pulmonx chartis tablet console		 Device Pulmonx Corporation $117,215.68 100 2025
Source payment records
ZEPHYR DELIVERY CATHETER
Normalized: zephyr delivery catheter		 Device Pulmonx Corporation $117,215.68 100 2025
Source payment records
OFEV
Normalized: ofev		 Drug Boehringer Ingelheim Pharmaceuticals, Inc. $2,410.37 3 2025
Source payment records
SPIRIVA RESPIMAT
Normalized: spiriva respimat		 Drug Boehringer Ingelheim Pharmaceuticals, Inc. $1,230.00 1 2025
Source payment records
BREZTRI
Normalized: breztri		 Drug AstraZeneca Pharmaceuticals LP $250.00 1 2025
Source payment records
INSPIRE
Normalized: inspire		 Device Inspire Medical Systems, Inc. $143.77 1 2025
Source payment records
OPSUMIT
Normalized: opsumit		 Drug Actelion Pharmaceuticals US, Inc. $121.37 1 2025
Source payment records
UPTRAVI
Normalized: uptravi		 Drug Actelion Pharmaceuticals US, Inc. $121.37 1 2025
Source payment records
TERLIVAZ
Normalized: terlivaz		 Drug Mallinckrodt Hospital Products Inc. $117.72 1 2025
Source payment records
ULTOMIRIS
Normalized: ultomiris		 Biological Alexion Pharmaceuticals, Inc. $117.72 1 2025
Source payment records
XPHOZAH 30 MG
Normalized: xphozah 30 mg		 Drug Ardelyx, Inc. $117.72 1 2025
Source payment records
ACTHAR
Normalized: acthar		 Biological Mallinckrodt Hospital Products Inc. $99.99 1 2025
Source payment records
Arikayce
Normalized: arikayce		 Drug Insmed, Inc. $87.66 1 2025
Source payment records
GLASSIA
Normalized: glassia		 Biological Takeda Pharmaceuticals U.S.A., Inc. $21.50 1 2025
Source payment records
JASCAYD
Normalized: jascayd		 Drug Boehringer Ingelheim Pharmaceuticals, Inc. $20.20 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $179,740.14 · 142 records Pulmonx Corporation ACTHAR, Arikayce, BREZTRI, CHARTIS CATHETER, GLASSIA, INSPIRE, JASCAYD, OFEV, OPSUMIT, PULMONX CHARTIS TABLET CONSOLE, SPIRIVA RESPIMAT, TERLIVAZ, ULTOMIRIS, UPTRAVI, XPHOZAH 30 MG, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error